Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study

Familial Cancer

Volumn 14, Issue 3, 2015, Pages 383-391

  Segev, Yakir ^a,b   Rosen, Barry ^b   Lubinski, Jan ^c   Gronwald, Jacek ^c   Lynch, Henry T ^d   Moller, Pal ^e   Kim Sing, Charmaine ^f   Ghadirian, Parviz ^g   Karlan, Beth ^h   Eng, Charis ⁱ   Gilchrist, Dawna ^j   Neuhausen, Susan L ^k   Eisen, Andrea ^l   Friedman, Eitan ^m   Euhus, David ⁿ   Ping, Sun ^a   Narod, Steven A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF ALBERTA   (Canada)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^l SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^m GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

BRCA1; BRCA2; Endometrial cancer; Tamoxifen

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MENARCHE; MENOPAUSE; ORAL CONTRACEPTIVE USE; OVARIECTOMY; PRIORITY JOURNAL; SMOKING; TREATMENT DURATION; ENDOMETRIAL NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; MIDDLE AGED; MUTATION; ODDS RATIO; PROCEDURES; RISK FACTOR;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; HYSTERECTOMY; MIDDLE AGED; MUTATION; ODDS RATIO; OVARIECTOMY; RISK FACTORS; TAMOXIFEN;

EID: 84941023298     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-015-9798-8     Document Type: Article

References (33)

1. Ferlay J, Bray F, Forman D, Mathers C, Parkin DM. SHR (2010) Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. GLOBOCAN 2008, International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr
2. Furness S, Roberts H, Marjoribanks J, Lethaby A, Hickey M, Farquhar C (2009) Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev CD000402. doi:10.1002/14651858.CD000402.pub3
3. Mourits MJ, De Vries EG, Willemse PH et al (2001) Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 97:855
4. Renehan AG, Tyson M, Egger M et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569
5. Moore SC, Gierach GL, Schatzkin A, Matthews CE (2010) Physical activity, sedentary behaviours, and the prevention of endometrial cancer. Br J Cancer 103:933
6. Xu WH, Xiang YB, Ruan ZX et al (2004) Menstrual and reproductive factors and endometrial cancer risk: results from a population-based case–control study in urban Shanghai. Int J Cancer 108:613
7. Karageorgi S, Hankinson SE, Kraft P, De Vivo I (2010) Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses’ Health Study cohort 1976–2004. Int J Cancer 126:208
8. Lucenteforte E, Talamini R, Montella M et al (2009) Family history of cancer and the risk of endometrial cancer. Eur J Cancer Prev 18:95
9. Lavie O, Ben-Arie A, Segev Y et al (2010) BRCA germline mutations in women with uterine serous carcinoma-still a debate. Int J Gynecol Cancer 20:1531–1534
10. Biron-Shental T, Drucker L, Altaras M, Bernheim J, Fishman A (2006) High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol 32:1097–1100
11. Goshen R, Chu W, Elit L et al (2000) Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast–ovarian cancer syndrome? Gynecol Oncol 79:477–481
12. Segev Y, Iqbal J, Lubinski J et al (2013) The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 130:127–131
13. Cosman F, Lindsay R (1999) Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 20:418
14. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609
15. McLaughlin JR, Risch HA, Lubinski J et al (2007) Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case–control study. Lancet Oncol 8:26
16. Mueck AO, Seeger H, Rabe T (2010) Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer 17:R263
17. Katzenellenbogen BS, Montano MM, Le Goff P et al (1995) Antiestrogens: mechanisms and actions in target cells. J Steroid Biochem Mol Biol 53:387
18. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771
19. Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652
20. Eisen A, Lubinski J, Gronwald J et al (2008) Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100:1361–1367
21. Kotsopoulos J, Lubinski J, Neuhausen SL et al (2006) Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 100:83–88
22. Henderson BE (1989) The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol 161:1859
23. Persson I, Adami HO, Bergkvist L et al (1989) Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 298:147
24. McPherson CP, Sellers TA, Potter JD et al (1996) Reproductive factors and risk of endometrial cancer. The Iowa Women’s Health Study. Am J Epidemiol 143:1195
25. Løchen ML, Lund E (1997) Childbearing and mortality from cancer of the corpus uteri. Acta Obstet Gynecol Scand 76:37
26. Zhou B, Yang L, Sun Q et al (2008) Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med 121:501
27. Widschwendter M, Rosenthal AN, Philpott S et al (2013) The sex hormone system in carriers of BRCA1/2 mutations: a case–control study. Lancet Oncol 14:1226–1232
28. Rajan JV, Marquis ST, Gardner HP, Chodosh LA (1997) Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. Dev Biol 184:385–401
29. King TA, Gemignani ML, Li W et al (2004) Increased progesterone receptor expression in benign epithelium of BRCA-1 related breast cancers. Cancer Res 64:5051–5053
30. Ma YX, Tomita Y, Fan S et al (2005) Structural determinants of the BRCA1: estrogen receptor interaction. Oncogene 24:1831–1846
31. Katiyar P, Ma Y, Fan S, Pestell RG, Furth PA, Rosen EM (2006) Regulation of progesterone receptor signaling by BRCA1 in mammary cancer. Nucl Recept Signal 4:e006
32. Setiawan VW, Yang HP, Pike MC et al (2013) Type I and II endometrial cancers: Have they different risk factors? J Clin Oncol 31:2607–2618
33. Visvanathan K, Hurley P, Bantug E et al (2013) Use of pharmacologic interventions for breast cancer risk reduction: American society of clinical oncology clinical practice guideline. J Clin Oncol 31:2942–2962